Pharmaceutical Regulatory Affairs
Regulatory Strategies for Pharmaceutical Development and Marketing Authorization
Pharmaceutical development and marketing authorization require a coordinated regulatory strategy integrating scientific, pharmaceutical, clinical, and quality-related requirements.
Avary Consulting supports pharmaceutical companies in addressing regulatory challenges, planning marketing authorization activities, and coordinating regulatory documentation and interactions with health authorities.
In Europe, our approach considers Directive 2001/83/EC, Regulation (EC) No 726/2004, and relevant guidance issued by the European Medicines Agency (EMA).
For international pharmaceutical development, we incorporate relevant ICH guidelines, including:
ICH Q8: Pharmaceutical Development
ICH Q9: Quality Risk Management
ICH Q10: Pharmaceutical Quality System
ICH M4: Common Technical Document (CTD)
For projects involving the U.S. market, we consider applicable FDA requirements, including 21 CFR Parts 210, 211, 312, and 314.
Our services include:
Pharmaceutical regulatory affairs strategies
Coordination of regulatory development and marketing authorization activities
Assessment of applicable EMA, FDA, and ICH requirements
Support for regulatory documentation planning
Preparation and coordination of regulatory authority interactions
Regulatory gap assessments and remediation
Our Recommendation: Early alignment among pharmaceutical development, quality management, clinical functions, and regulatory affairs supports consistent submission documentation and more efficient preparation for regulatory decisions.